Haemophilia B: Christmas disease

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 9, 2005, Pages 1517-1524

  Giangrande, Paul ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Coagulation factors; Haemophilia; Inhibitors; Recombinant

Indexed keywords

ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING INHIBITOR; FRESH FROZEN PLASMA; IMMUNOGLOBULIN G; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 9; TRANEXAMIC ACID; TRITON X 100;

ANION EXCHANGE CHROMATOGRAPHY; APHERESIS; ARTHRITIS; ARTHROPATHY; BLOOD DONOR; CRYOPRECIPITATE; DEVELOPING COUNTRY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG PURITY; DRUG SAFETY; DRUG UTILIZATION; FRACTIONATION; GENE THERAPY; HEAT TREATMENT; HEMARTHROSIS; HEMOPHILIA B; HEMOSTASIS; HUMAN; IMMUNOLOGICAL TOLERANCE; INHERITANCE; MEDICAL DECISION MAKING; MEMBRANOUS GLOMERULONEPHRITIS; MUCOSAL BLEEDING; NANOFILTRATION; PHENOTYPE; PHYSICAL DISABILITY; PLASMA TRANSFUSION; POINT MUTATION; QUALITY CONTROL; REVIEW; UNITED KINGDOM; VIRUS INACTIVATION;

ANTIFIBRINOLYTIC AGENTS; AUTOANTIBODIES; CLINICAL TRIALS; DEVELOPING COUNTRIES; FACTOR IX; FACTOR VIIA; FACTOR VIII; FORECASTING; GENE THERAPY; GREAT BRITAIN; HEMARTHROSIS; HEMOPHILIA B; HUMANS; PRACTICE GUIDELINES; PREMEDICATION; RECOMBINANT PROTEINS; TRANEXAMIC ACID;

EID: 23644441511     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.9.1517     Document Type: Review

References (49)

1. WHITE GC II, ROSENDAAL F, ALEDORT LM, LUSHER JM, ROTHSCHILD C, INGERSLEV J: Definitions in hemophilia: recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb. Haemost. (2001) 85:560.
2. RIZZA CR, SPOONER RJD, GIANGRANDE PLF ON BEHALF OF THE UK HAEMOPHILIA CENTRE DOCTORS' ORGANISATION (UKHCDO): Treatment of haemophilia in the United Kingdom 1981-1996. Haemophilia (2001) 7:349-359.
3. BOLTON-MAGGS PHB, PASI JK: Haemophilias A and B. Lancet (2003) 361:1801-1809.
4. ROYAL S, SCHRAMM W, BERNTORP E et al.: Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia (2002) 8:44-50.
5. DARBY SC, KEELING DM, SPOONER RJD et al.: The incidence of factor VIII and IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J. Thromb. Haemost. (2004) 2:1047-1054.
6. GIANGRANDE PLF: Six characters in search of an author: the history of the nomenclature of coagulation factors. Br. J. Haematol. (2003) 121:703-712.
7. BIGGS R, DOUGLAS AS, MACFARLANE RG: Christmas disease: a condition previously mistaken for haemophilia. BMJ (1952) 2(4799):1378-1382.
8. GREEN PM: Hemophilia B-molecular basis. In: Textbook of Hemophilia. Lee CA, Berntorp EE, Hoots WK (Eds) Blackwell Publishing, Oxford (2005):91-96.
9. CROSSLEY M, BROWNLEE GG: Disruption of a C/EBP binding site in the factor IX promoter is associated with haemophilia B. Nature (1990) 345:444-446.
10. FARRUGIA A: Guide for the assessment of clotting factor concentrates for the treatment of hemophilia. World Federation of Hemophilia, Montreal, (2003).
11. UNITED KINGDOM HAEMOPHILIA CENTRE DOCTORS' ORGANISATION (UKHCDO): Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia (2003) 9:1-23.
12. GIANGRANDE PLF: Treatment of hemophilia: recombinant products only? Yes. J. Thromb. Haemost. (2003) 1:214-215.
13. MANNUCCI PM: Treatment of hemophilia: recombinant products only? No. J. Thromb. Haemost. (2003) 1:216-217.
14. BROWNLEE GG, GIANGRANDE PLF: Clotting factors VIII and IX In: Recombinant Protein Drugs ('Milestones in Drug Therapy' series) Birkhäuser (2001).
15. HOROWITZ MS, ROOKS C, HOROWITZ B, HILGARTNER MW: Virus safety of solvent/detergent-treated antihaemophilic factor concentrate. Lancet (1988) 2(8604):186-189.
16. SCHIMPF K, BRACKMANN HH, KREUZ W et al.: Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrate. N. Engl. J. Med. (1989) 321:1148-1152.
17. RIZZA CR, FLETCHER ML, KERNOFF PB: Confirmation of viral safety of dry heated factor VIII concentrate (8Y) prepared by Bio Products Laboratory (BPL): a report on behalf of U.K. Haemophilia Centre Directors. Br. J. Haematol. (1993) 84:269-272.
18. VERMYLEN J, PEERLINCK K: Review of the hepatitis A epidemics in hemophiliacs in Europe. Vox Sanguinis (1994) 67(Suppl. 4):8-11.
19. SOUCIE JM, ROBERSTON BH, BELL BP, MCCAUSTLAND KA, EVATT BL: Hepatitis A virus infections associated with clotting factor concentrate in the United States. Transfusion (1998) 38:573-579.
20. YEE TT, COHEN BJ, PASI KJ, LEE CA: Transmission of symptomatic parvovirus parvovirus B19 infection by clotting factor concentrate. Br. J. Haematol. (1996) 93:457-459.
21. AZZI A, MORFINI M, MANNUCCI PM: The transfusion-associated transmission of parvovirus B19. Trans. Med. Rev. (1999) 13:194-204.
22. BURNOUF T, RADOSEVICH M: Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia (2003) 9:24-37.
23. MAKRIS M, CONLON CP, WATSON HG: Immunization of patients with bleeding disorders. Haemophilia (2003) 9:541-546.
24. FARRUGIA A: Risk of variant Creutzfeldt-Jakob disease from factor concentrates: current perspectives. Haemophilia (2002) 8:230-235.
25. THOMAS DP, HAMPTON KK, DASANI H et al.: A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate. Br. J. Haematol. (1994) 87:782-788.
26. KASPER CK: Thromboembolic complications. Thrombosis et Diathesis Haemorrhagica (1975) 33:640-644.
27. CONLAN MG, HOOTS WK: Disseminated intravascular coagulation and hemorrhage in hemophilia B following elective surgery. Am. J. Hematol. (1990) 35:203-207.
28. FUERTH JH, MAHRER P: Myocardial infarction after factor IX therapy. J. Am. Med. Ass. (1981) 245:1455-1456.
29. ROTH DA, KESSLER CM, PASI KJ, RUP B, COURTER SG, TUBRIDY K FOR THE RECOMBINANT FACTOR IX STUDY GROUP: Human recombinant factor IX. Safety and efficacy studies in patients with hemophilia B. Blood (2001) 98:3600-3606.
30. RAGNI MV, PASI KJ, WHITE GC, GIANGRANDE PL, COURTER SG, TUBRIDY KL FOR THE RECOMBINANT FIX SURGICAL STUDY GROUP: Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. Haemophilia (2002) 8:91-97.
31. SHAPIRO AD, DI PAOLA J, COHEN A et al.: The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood (2005) 105:518-525.
32. BLANCHETTE P, RIVARD G, ISRAELS S et al.: A survey of factor prophylaxis in the Canadian haemophilia A population. Haemophilia (2004) 10:679-683.
33. AHNSTRÖM J, BERNTORP E, LINDVALL K, BJÖRKMAN S: A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia (2004) 10:689-697.
34. BERNTORP E, ASTERMARK J, BJORKMAN S et al.: Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia (2003) 9(Suppl. 1):1-4.
35. POON MC, LILLICRAP D, HENSMAN C, CARD R, SCULLY MF: Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thromb. Haemost. (2002) 87:431-435.
36. EWENSTEIN BM, JOIST JH, SHAPIRO AD et al. FOR THE MONONINE COMPARISON STUDY GROUP: Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion (2002) 42:190-197.
37. KISKER CT, EISBERG A, SCHWARTZ B AND THE MONONINE STUDY GROUP: Prophylaxis in factor IX deficiency product and patient variation. Haemophilia (2003) 9:279-284.
38. BJÖRKMAN S, SHAPIRO AD, BERNTORP E: Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia (2001) 7:133-139.
39. KERNOFF PB, DURRANT IJ, RIZZA CR, WRIGHT FB. Severe allergic pulmonary oedema after plasma transfusion. Br. J. Haematol. (1972) 23:777-781.
40. RIEDLER GF, HAYCOX AR, DUGGAN AK, DAKIN HA: Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sanguinis 20085:88-95.
41. GIANNELLI F, CHOO KH, REES DJ, BOYD Y, RIZZA CR, BROWNLEE GG: Gene deletions in patients with haemophilia B and anti-factor IX antibodies. Nature (1983) 303:181-182.
42. WARRIER I: Management of haemophilia B patients with inhibitors and anaphylaxis. Haemophilia (1998) 4:574-576.
43. KEY NS: Inhibitors in congenital coagulation disorders. Br. J. Haematol. (2004) 127:379-391.
44. EWENSTEIN MB, TAKEMOTO C, WARRIER I et al.: Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood (1997) 89:115-116.
45. WARRIER I, LENK H, SALDI P, POLLMAN H, TENGBORN L, BERNTORP E: Nephrotic syndrome in hemophilia B patients with inhibitors. Haemophilia (1998) 4:248-251.
46. VAN COTT KE, MONAHAN PE, NICHOLS TC, VELANDER WH: Hemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide. Haemophilia (2004) 10(Suppl. 4):70-76.
47. HIGH KA: Adeno-associated virus-mediated gene transfer for hemophilia B. Int. J. Hematol. (2002) 76:310-318.
48. CHUAH MKL, COLLEN D, VANDENDRIESSCHE T: Preclinical and clinical gene therapy for haemophilia. Haemophilia (2004) 10(Suppl. 4):119-125.
49. KAY MA, MANNO CS, RAGNI MV et al.: Evidence for gene transfer and expression of factor IX in haemophilia B treated with an AAV vector. Nat. Genet. (2000) 24:257-261.